Nevro Corp. (NVRO)
| Market Cap | 5.23B |
| Revenue (ttm) | 362.05M |
| Net Income (ttm) | -83.07M |
| Shares Out | 33.68M |
| EPS (ttm) | -2.47 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 5 |
| Last Price | $151.12 |
| Previous Close | $155.70 |
| Change ($) | -4.58 |
| Change (%) | -2.94% |
| Day's Open | 157.14 |
| Day's Range | 146.66 - 158.50 |
| Day's Volume | 588,045 |
| 52-Week Range | 65.05 - 188.14 |
Nevro's (NVRO) domestic and international revenues fell on a year-over-year basis in the fourth quarter.
Shares of Nevro (NYSE:NVRO) moved lower in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 52.27% year over year to ($0.21), which be...
REDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., Jan. 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
If you desire growth, then your sights should be set on small-cap stocks. These 11 have attracted the gaze of dozens of Wall Street's best minds.
Nevro's (NVRO) preliminary worldwide Q4 revenues are expected to decline from the year-ago quarter's figure.
Nevro's (NVRO) submission of a pre-market approval supplement to the FDA to seek approval for its Senza System can help in the treatment of chronic pain associated with PDN.
REDWOOD CITY, Calif., Dec. 28, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
REDWOOD CITY, Calif., Dec. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
Nevro has been prospering in its chosen specialty of opioid-free pain relief. Nevro's Omnia launch has been dampened by the pandemic; expect good things as the pandemic moves to the rear.
REDWOOD CITY, Calif., Dec. 15, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
MARLBOROUGH, Mass., Dec. 14, 2020 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYSE: NVRO)...
REDWOOD CITY, Calif., Dec. 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
Investors grew bullish on Nevro's (NVRO) prospects, courtesy of the stock's solid prospects.
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
REDWOOD CITY, Calif., Nov. 30, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chroni...
Nevro's (NVRO) domestic and international revenues increased on a year-over-year basis in the third quarter.
Nevro Corp. (NVRO) CEO Keith Grossman on Q3 2020 Results - Earnings Call Transcript
Nevro (NVRO) delivered earnings and revenue surprises of 50.85% and 4.17%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nevro (NVRO) continues to gain traction from its flagship platform, Senza, and R&D capabilities. However, stiff competition remains a woe.
Nevro (NVRO) commences plan for manufacturing operations in Costa Rica, thereby expanding its geographic footprint and boosting growth prospects.
REDWOOD CITY, Calif., Sept. 14, 2020 /PRNewswire/ -- Nevro Corp.
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
REDWOOD CITY, Calif., Sept. 1, 2020 /PRNewswire/ -- Nevro Corp.
A Relative Strength Rating upgrade for Nevro shows improving technical performance.
Nevro's (NVRO) domestic and international revenues declined on a year-over-year basis in Q2.
REDWOOD CITY, Calif., Aug. 7, 2020 /PRNewswire/ -- Nevro Corp.
Nevro Corp (NVRO) CEO Keith Grossman on Q2 2020 Results - Earnings Call Transcript
Nevro (NVRO) delivered earnings and revenue surprises of 26.67% and 36.02%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
REDWOOD CITY, Calif., July 20, 2020 /PRNewswire/ -- Nevro Corp.
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
REDWOOD CITY, Calif., June 4, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic...
Nevro (NVRO) received CE mark approval for the Senza Omnia SCS system, which is likely to boost its international presence.
REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic...
Nevro's (NVRO) domestic revenues improved on a year-over-year basis in Q1.
Nevro Corp (NVRO) CEO Keith Grossman on Q1 2020 Results - Earnings Call Transcript
Nevro (NVRO) delivered earnings and revenue surprises of 24.27% and 0.98%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Nevro (NVRO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Nevro (NVRO) reported earnings 30 days ago. What's next for the stock?
Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.
Nevro (NVRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Nevro (NVRO) sees strong segmental contributions in Q4.
Nevro Corp (NVRO) CEO Keith Grossman on Q4 2019 Results - Earnings Call Transcript
Nevro (NVRO) delivered earnings and revenue surprises of 29.03% and 3.20%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
About NVRO
Nevro, a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. In addition, the company provides HF10 Therapy, which delivers neuromodulation solutions for treating chronic pain based on available clinical evidence. It sells its products through its direct sales force, and ... [Read more...]
| Industry Medical Devices | IPO Date Nov 6, 2014 |
| CEO D.Keith Grossman | Employees 843 |
| Stock Exchange NYSE | Ticker Symbol NVRO |
Financial Performance
In 2020, Nevro Corp.'s revenue was $362.05 million, a decrease of -7.23% compared to the previous year's $390.26 million. Losses were -$83.07 million, -19.89% less than in 2019.
Analyst Forecasts
According to 15 analysts, the average rating for Nevro Corp. stock is "Buy." The 12-month stock price forecast is 199.50, which is an increase of 32.01% from the latest price.